Syndax Pharmaceuticals Inc (SNDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Syndax Pharmaceuticals Inc (SNDX) has a cash flow conversion efficiency ratio of -2.005x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-30.27 Million) by net assets ($15.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Syndax Pharmaceuticals Inc for the company's overall valuation and market capitalisation.
Syndax Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Syndax Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Syndax Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Syndax Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore Syndax Pharmaceuticals Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Deterra Royalties Ltd
AU:DRR
|
0.623x |
|
Dongguan Development Holdings Co Ltd
SHE:000828
|
0.081x |
|
Vaisala Oyj A
HE:VAIAS
|
0.050x |
|
Shanghai Tofflon Science Tech
SHE:300171
|
0.006x |
|
Kiatnakin Phatra Bank Public Company Limited
BK:KKP-R
|
0.158x |
|
Pharma Mar S.A.
MC:PHM
|
0.133x |
|
GUARANTY TR.HLDG.GDR REGS
F:9JO
|
N/A |
|
Swan Energy Limited
NSE:SWANENERGY
|
-0.037x |
Annual Cash Flow Conversion Efficiency for Syndax Pharmaceuticals Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Syndax Pharmaceuticals Inc from 2011 to 2025. View today's stock price for Syndax Pharmaceuticals Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $64.63 Million | $-322.98 Million | -4.997x | -423.77% |
| 2024-12-31 | $288.12 Million | $-274.90 Million | -0.954x | -229.24% |
| 2023-12-31 | $554.20 Million | $-160.60 Million | -0.290x | -1.34% |
| 2022-12-31 | $467.45 Million | $-133.68 Million | -0.286x | -500.88% |
| 2021-12-31 | $408.37 Million | $29.13 Million | 0.071x | +125.25% |
| 2020-12-31 | $252.19 Million | $-71.26 Million | -0.283x | +82.36% |
| 2019-12-31 | $31.60 Million | $-50.61 Million | -1.602x | -23.98% |
| 2018-12-31 | $53.05 Million | $-68.53 Million | -1.292x | -184.50% |
| 2017-12-31 | $104.32 Million | $-47.37 Million | -0.454x | -8.68% |
| 2016-12-31 | $84.14 Million | $-35.16 Million | -0.418x | -1047.83% |
| 2015-12-31 | $66.70 Million | $-2.43 Million | -0.036x | -101.45% |
| 2014-12-31 | $-5.72 Million | $-14.39 Million | 2.518x | +508.99% |
| 2013-12-31 | $11.85 Million | $-7.29 Million | -0.616x | -294.22% |
| 2012-12-31 | $-29.29 Million | $-9.28 Million | 0.317x | -39.73% |
| 2011-12-31 | $-19.05 Million | $-10.02 Million | 0.526x | -- |
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. Th… Read more